Hemostemix Inc. (CVE:HEM – Get Free Report) shares rose 14.3% during trading on Friday . The stock traded as high as C$0.40 and last traded at C$0.40. Approximately 813,546 shares traded hands during trading, an increase of 19% from the average daily volume of 681,348 shares. The stock had previously closed at C$0.35.
Hemostemix Trading Up 7.1 %
The business’s fifty day moving average price is C$0.13 and its two-hundred day moving average price is C$0.09. The firm has a market cap of C$32.67 million, a P/E ratio of -18.75 and a beta of 0.20.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Recommended Stories
- Five stocks we like better than Hemostemix
- Market Cap Calculator: How to Calculate Market Cap
- Bloom Energy: Powering the Future With Decentralized Energy
- What is the MACD Indicator and How to Use it in Your Trading
- Dividend Powerhouses: Blue-Chip Stocks Built for the Long Haul
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Why Traders Are Buying the Dip on Johnson & Johnson Stock
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
